Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O15013
UPID:
ARHGA_HUMAN
Alternative names:
-
Alternative UPACC:
O15013; O14665; Q2KHR8; Q68D55; Q8IWD9; Q8IY77
Background:
Rho guanine nucleotide exchange factor 10 (RhoGEF10) is a pivotal protein implicated in the regulation of the Rho family GTPases, key modulators of the cytoskeleton organization. This protein's involvement in developmental myelination of peripheral nerves highlights its critical role in nerve function and structure.
Therapeutic significance:
The association of RhoGEF10 with slowed nerve conduction velocity, a condition characterized by reduced nerve conduction speeds without overt neurological dysfunction, underscores its therapeutic potential. Understanding the role of Rho guanine nucleotide exchange factor 10 could open doors to potential therapeutic strategies for improving nerve conduction and treating related neuropathies.